RARE News and Press, Ultragenyx Pharmaceutical Inc. From 06/06/24

2024-06-06 15:42:20 ET Summary Ultragenyx Pharmaceutical Inc. revenues from regulatory approved drugs in Q1 of 2024 were $109 million, representing sales growth of 8% compared to the same time period in 2023. Setrusumab is an anti-sclerostin monoclonal antibody being developed for...

2024-06-06 07:49:18 ET More on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet Ultragenyx Phase 3 study for DTX401 meets primary endpoint Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $...

NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the comp...

2024-05-31 16:15:04 ET Barclays analyst issues OVERWEIGHT recommendation for RARE on May 31, 2024 02:33PM ET. The previous analyst recommendation was Overweight. RARE was trading at $40.415 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-30 16:32:10 ET More on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28,...

Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m. ET NOVATO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutica...

2024-05-23 15:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's c...

2024-05-02 20:28:09 ET Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Conference Call May 02, 2024, 17:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Ch...

2024-05-02 16:02:32 ET More on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript Ultragenyx Pharmaceutical Q1 2024 Earnings Preview As...